SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : The Residential Real Estate Post-Crash Index-Moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Smiling Bob who wrote (119220)6/27/2023 10:23:35 AM
From: Smiling Bob   of 119358
 
Naming it Heeroin

Eli Lilly shares gain after investigational obesity treatment helps patients lose up to 58 pounds, on average
7:54 am ET June 27, 2023 (MarketWatch)

Print
Shares of Eli Lilly & Co. (LLY) gained 1.6% premarket on Tuesday after the company released new data late Monday on its investigational obesity drug retatrutide. The treatment resulted in average weight loss of up to 17.5%, or 41.2 pounds, after 24 weeks in patients with obesity or overweight and without diabetes, and average weight loss of up to 24.2%, or 57.8 pounds, after 48 weeks, according to results presented at the American Diabetes Association's scientific conference. "These data firmly place Lilly in the lead of the 'metabolic revolution' driven by incretin therapy," BMO Capital Markets analyst Evan David Seigerman wrote in a research note Monday. Lilly shares have gained 24% in the year to date, compared with 13% for the S&P 500.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News